Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Upgrades AnaptysBio to Buy

Guggenheim Upgrades AnaptysBio to Buy

Guggenheim analyst Yatin Suneja upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy.

byBenzinga Newsdesk

November 1, 2022

1 minute read

Guggenheim analyst Yatin Suneja upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy.

Analyst Ratings

The Latest Analyst Ratings for Asana

By Benzinga Insights

October 4, 8:00 AM

Analysts have provided the following ratings for Asana (NYSE:ASAN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

ASAN

Analyst Ratings

7 Analysts Have This To Say About Amgen

By Benzinga Insights

April 3, 11:00 AM

Analysts’ ratings for Amgen (NASDAQ:AMGN) over the last quarter vary from bullish to bearish, as provided by 7…

AMGN

News

DatChat Launches Artificial Intelligence Powered Pets In Its Habytat Virtual World

By Happy Mohamed

August 16, 8:05 AM

Shiba Inu, German Shepherd, Golden Retriever, and Schnauzer are the first breeds to launch using novel machine learning framework that replicates life-like interactions and training DatChat (NASDAQ:DATS), announced

DATS

DA Davidson Maintains Neutral on Okta, Lowers Price Target to $80

By Benzinga Newsdesk

September 1, 10:00 AM

DA Davidson analyst Rudy Kessinger maintains Okta (NASDAQ:OKTA) with a Neutral and lowers the price target from $105 to $80.

OKTA

Guggenheim Upgrades AnaptysBio to Buy

Related Posts

The Latest Analyst Ratings for Asana

7 Analysts Have This To Say About Amgen

DatChat Launches Artificial Intelligence Powered Pets In Its Habytat Virtual World

DA Davidson Maintains Neutral on Okta, Lowers Price Target to $80